The simian immunodeficiency viruses (SIV) are a polymorphic family of viruses that share approximately 50% amino acid identity in gag or pol genes between subgroups (20, 27) . However, the family can be subclassified into more closely related groups on the basis of the species of origin of a specific isolate. As recently reviewed (20) , five SIV groups have been presently characterized: (i) SIVsm from sooty mangabeys (Cercocebus atys), (ii) SIVagm from African green monkeys (Cercopithecus aethiops), (iii) SIVmnd from mandrill monkeys, (iv) SIVsyk from Sykes' monkeys (Cercopithecus mitis), and (v) SIVcpz from chimpanzees (Pan troglodytes). Some of these groups can be further subdivided; thus, the SIVsm group also includes SIVmac isolated from captive macaques (8) and human immunodeficiency virus type 2. Similarly, the SIVagm group consists of at least four related subtypes isolated from the tantalus (SIVtan), vervet (SIVver), grivet (SIVgri), and sabaeus (SIVsab) species of African green monkeys (2-4, 10, 13, 14, 20, 23, 24, 29) . SIV is highly prevalent within naturally infected primates, i.e., 10 to 60% seroprevalence (2, 3, 9, 17, 33, 36) in feral African monkey populations. Despite this high seroprevalence, there is no evidence that natural infection results in clinical disease, specifically immunodeficiency, in these animals (1, 18) . This lack of disease association is apparently characteristic of each of the African species naturally infected in the wild.
Although naturally infected sooty mangabey monkeys remain healthy, passage of the SIVsm virus to Asian species, such as macaques, results in an AIDS-like syndrome that is similar in many respects to human AIDS (1, 5, 18, 26, 30, 31, 34, 38, 39) . Therefore, SIVsm and SIVmac infection of macaques has become a useful animal model for the study of AIDS pathogenesis and for vaccine development (11) . Macaques infected with SIVsm or SIVmac experience a period of acute plasma-and cell-associated viremia, followed by a progressive decline in the number of circulating CD4 lymphocytes which precedes the onset of clinical symptoms (1, 6, 18, 31, 37, 41) . Early signs of disease include progressive weight loss, failure to thrive, chronic diarrhea, and lymphadenopathy (7) . Infected macaques eventually develop opportunistic infections such as Pneumocystis carinii pneumonia, Mycobacterium avium lymphadenitis and enteritis, candidiasis, adenovirus pancreatitis, and disseminated cytomegalovirus infections within months or years of infection (5, 31, 34, (38) (39) (40) (41) . A significant number of animals also develop symptoms of central nervous system pathology (40) similar to lesions observed in AIDS dementia patients.
The majority of SIV pathogenesis and vaccine studies have utilized SIVsm or SIVmac infection of macaques. Isolates from other SIV groups have not been characterized as extensively in terms of pathogenesis, and it has been generally assumed that SIVmnd, SIVagm, and SIVsyk are nonpathogenic both for their natural host and in experimentally inoculated macaques. For example, experimental inoculation of cynomolgus or rhesus macaques with SIVagm strains results in persistent infection with a characteristically low virus load and no associated disease (1, 4, 22, 24) . A similar finding was observed for ma-caques inoculated with SIVsyk (20) . However, generalizing about the overall pathogenicity of the whole subgroup of SIVagm on the basis of these limited experiments may be misleading. For example, at least two macaques infected with SIVagm strains have developed an AIDS-like disease. One study reported a pig-tailed (PT) macaque (Macaca nemestrina) infected with SIVagm155 uncloned virus that died with Pneumocystis pneumonia (15) . In addition, SIVagm90 isolated from a naturally infected vervet monkey from the same colony as Agm155 induced a persistent CD4 depletion in experimentally inoculated PT macaques. One of these animals (PT63) developed a disseminated M. avium infection that necessitated sacrifice at 12 months postinoculation. SIV was readily isolated from tissues of this animal, and the virus was designated SIVagm9063.
The goal of the present study was to biologically and molecularly characterize this PT-macaque-passaged SIVagm and determine whether the infection of animals induced an immunodeficiency syndrome. Specifically, the spleen of the immunodeficient PT63 was used to isolate virus that was passaged to naive PT macaques and as a source of genomic DNA for a bacteriophage lambda library. Clones derived from this library were subsequently analyzed on a molecular level and tested for pathogenicity in PT macaques.
MATERIALS AND METHODS
Virus isolation and animal passage. The isolation of SIVagm90 has been described in a previous report (18, 23) . Briefly, virus was isolated from the naturally infected Agm90 by cocultivation of peripheral blood mononuclear cells (PBMC) with the human CD4 ϩ cell line CEMss. The culture supernatants were monitored for reverse transcriptase (RT) activity, harvested as cell-free virus stocks, and cryopreserved for subsequent animal studies. Two PT macaques were inoculated intravenously with SIVagm90 stock and became persistently infected, as evidenced by seroconversion and virus isolation from PBMC. The numbers of circulating CD4 lymphocytes declined in both animals, and one animal (PT63) was sacrificed with a disseminated M. avium infection at 12 months postchallenge. Virus was isolated by cocultivation of CEMss cells with homogenates of cryopreserved splenic tissue collected at necropsy and designated SIVagm9063. Genomic DNA isolated from the PT63 spleen-CEMss isolate was used for subsequent molecular analysis, and cell-free supernatants were used to inoculate macaques.
Molecular cloning and analysis. Genomic DNA from the CEMss isolate of SIVagm9063 was subjected to restriction digestion with various enzymes and Southern blot analysis using a full-length SIVagm155-4 probe under conditions of high stringency (21) . This analysis demonstrated no internal EcoRI, BamHI, or XbaI sites in the virus genome. EcoRI-digested genomic DNA was size selected (9 to 20 kb) on a 10 to 40% sucrose gradient and ligated into EcoRIdigested lambda DASH II (Stratagene, La Jolla, Calif.), and the library was packaged with Gigapak Gold (Stratagene) packaging extracts. Approximately 5 ϫ 10 5 recombinant plaques were screened by use of the full-length SIVagm155-4 probe, and four clones were purified to homogeneity (clones 2, 7, 16, and 26). Large-scale liquid cultures of each clone were produced and purified with lambda DNA, and a rough restriction map of each clone was generated. One was a partial 5Ј-end clone (clone 16), and the other three contained full-length proviral genomes. To facilitate sequence analysis, the EcoRI inserts of two of the clones (clones 2 and 7) were subcloned into pGEM-7Zf plasmid vector that had been digested with EcoRI and treated with calf intestinal alkaline phosphatase (Boehringer Mannheim). The viral insert of clone 2 was further subcloned into two portions (5Ј XhoI to SphI and 3Ј SstI to EcoRI) and sequenced with T7 polymerase (Sequenase II; U.S. Biochemical Corp.). The sequence was analyzed with the Intelligenetics suite of programs (SEQ and GENALIGN) and the PCGene programs.
Tissue culture and cells. Virus was isolated from frozen splenic tissue from PT63 by cocultivation of splenic homogenate with CEMss cells. Cryopreserved splenic tissue was thawed on ice and subjected to Dounce homogenization in Hanks buffered saline solution to disrupt the cells from connective tissue. This homogenate (1 ml) was then cocultivated with CEMss cells, and the cultures were monitored for RT activity and filtered culture supernatants were collected at the peak of RT activity.
The lambda clones were tested for infectivity by transfection of CEMss cells and 293 cells (human embryonic kidney cells transformed with adenovirus E1a and E1b; American Type Culture Collection) by a modification of the DEAEdextran transfection and calcium phosphate-mediated (CellPhect; Pharmacia) methods, respectively. Transfected cultures were monitored for RT activity in the culture supernatant, and cell-free supernatants were harvested and cryopreserved at the peak of RT activity. These stocks were used to test for infectivity of macaque PBMC and monocyte-derived macrophages by incubation with the target cells for 1 h at 37ЊC, removal of residual virus by washing with Hanks buffered saline solution, and culture of cells in an appropriate medium (RPMI 1640 with 10% interleukin-2 and 10% fetal calf serum for PBMC and RPMI 1640 with 10% fetal calf serum and 10% normal macaque serum for monocyte-derived macrophages), as described previously for other SIV strains (19) .
Animal inoculations. A total of eight PT macaques were inoculated intravenously with either cell-free supernatants from the CEMss isolate of SIVagm9063 from the spleen of PT63 (n ϭ 4) or homogenates of PT63 spleen (n ϭ 4). These macaques were seronegative for both simian T-cell lymphotrophic virus type I and simian retrovirus, as determined by serology tests. No contemporary mockinoculated macaques were maintained as a reference; therefore, the acute alterations in lymphocyte subsets, hematocrit and platelet counts were verified by using historical data on uninfected macaques. Two rhesus macaques (Macaca mulatta) and two African green monkeys (C. sabaeus) were also inoculated with the splenic CEMss isolate. Following molecular cloning and transfection, eight PT macaques were inoculated with progeny virus of clone 2. The monkeys were monitored for evidence of infection by periodic lymphocyte subset analysis, hematology, virus isolation from PBMC and plasma, and SIV-specific antibodies. Virus isolation from infected animals was performed by cocultivation of CEMss cells with 5 ϫ 10 6 PBMC that had been cultured for 4 days in RPMI 1640 in the presence of 10% interleukin-2 and 5 g of phytohemagglutinin per ml. Growth of cultures was continued after cocultivation in media lacking phytohemagglutinin and was monitored weekly for RT activity over a 6-week period. SIV p27 antigen in the plasma was detected by cross-reactivity with the SIVmac antigen capture kit (Coulter Corp., Hialeah, Fla.). Strips for Western blot (immunoblot) analysis with SIVagm90 virus lysate as the antigen were prepared. First, SIVagm90 was purified from filtered culture supernatants by centrifugation over a 20% sucrose (in phosphate-buffered saline [PBS]) cushion. The virus pellet from 90 ml of culture supernatant was resuspended in radioimmunoprecipitation assay buffer, mixed with sample buffer, boiled for 5 min, and loaded onto a preparative sodium dodecyl sulfate [SDS]-polyacrylamide (12%) gel.
Lymphocyte immunophenotyping. Lymphocyte subsets (CD2, CD20, CD4, and CD8) were analyzed sequentially throughout the infection by fluorescenceactivated cell sorter analysis using a Coulter Epics 753 (assays were performed by FAST Systems, Inc., Gaithersburg, Md.). Monkey peripheral blood leukocytes were stained with monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (Becton Dickinson), or RD-1 (Coulter Immunology). Heparinized whole-blood samples were incubated for 20 min in the dark at 4ЊC in the presence of sodium azide with the appropriate monoclonal antibody conjugate. Following staining, erythrocytes were lysed and the leukocytes were fixed in 1% paraformaldehyde and analyzed with a Flow cytometer. The monoclonal antibodies used for PT and rhesus macaque subsets were OKT4 (FITC) (Ortho Diagnostic Systems, Raritan, N.J.) to identify CD4 lymphocytes, Leu2a (FITC) for CD8 lymphocytes, T11 (phycoerythrin) for CD2 lymphocytes (Dako, Inc.) to identify T lymphocytes, and Leu16 (FITC) to identify CD20 expressed on B lymphocytes. The same procedure was used for African green monkey lymphocytes, with substitution of OKT4a (FITC) for CD4, GC2 (FITC) for CD8, and Leu2 (phycoerythrin) for CD2. These monoclonal antibodies were selected on the basis of their ability to stain appropriate subsets from samples collected from normal monkeys of these species. Generally, the normal range for CD4 lymphocytes in PT macaques was lower than that observed in rhesus macaques. In contrast, peripheral blood of normal uninfected African green monkeys contained a much lower proportion of CD4, CD8, and B cells than that of either of the macaque species.
Generation of riboprobes for in situ hybridization. Five contiguous 1.5-to 2-kb clones of SIVagm9063-2 that together spanned the entire genome were derived by PCR amplification using the full-length plasmid as a template. The following primers used for amplification incorporated a 5Ј BamHI site (Forward) and a 3Ј EcoRI site (Reverse): Agm90-AF (80), 5ЈTACGGATCCGCGGACGG TACCAATGGGGGC 3Ј; Agm90-AR (1620), 5ЈGTTGAATTCTATTGGTC TTCTCCAAAGAGG 3Ј; Agm90-BF (1620), 5Ј TACGGATCCCCAATAAAA ACAGTCATTATT 3Ј; Agm90-BR (3135), 5Ј GTTGAATTCCACTTGCCAGT AGTCTGCCCA 3Ј; Agm90-CF (3135), 5Ј TACGGATCCCAAGTGAGCT GGATTCCTGAA 3Ј; Agm90-CR (4635), 5Ј GTTGAATTCCCTCTTTCTGG TGTTAAATGC 3Ј; Agm90-DF (4635), 5Ј TACGGATCCAAGAGGCTGGCT CTCTACTTA 3Ј; Agm90-DR (6615), 5Ј GTTGAATTCAATTAAACCACAA ATTTGCTG 3Ј; Agm90-EF (6615), 5Ј TACGGATCCTTAATTGCCAGGG AGAGTTCT 3Ј; and Agm90-ER (8613), 5Ј GTTGAATTCCAGTTTCAAATG TCATCTCCC 3Ј. The positions of the 5Ј nucleotide in each primer relative to the complete sequence of SIVagm9063-2 are shown in parentheses, and the restriction sites are underlined. The PCR products were gel purified and cloned individually into the plasmid vector pGEM-7Zf (Promega) and were designated clones A, B, C, D, and E. The clones were linearized with BamHI to generate templates for the antisense probe, which were labeled A1 through E1. EcoRIdigested plasmid was used as the template for generating the sense probe. These linearized templates were pooled and transcribed, utilizing Sp6 or T7 to generate an antisense RNA probe and a sense probe labeled with digoxigenin.
In situ hybridization. Formalin-fixed, paraffin-embedded tissues were sectioned (4-to 5-m thickness) and placed on DEPC water-N-tris(hydromethyl) methyl-2-aminoethanesulfonic acid (TES)-coated glass slides before being dried at room temperature overnight. The slides were then heated for 5 min and were then washed sequentially (twice for 5 min) in a mixture of xylene, 100% ethanol, 95% ethanol, and DEPC-treated water. The slides were then incubated with 5 mM levamisole for 20 min, 1ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate) for 2 min, and a solution containing 25 g of proteinase K per ml in 10 mM Tris (pH 7.4) and 0.2 mM CaCl 2 at 37ЊC for 10 min before further incubations in 0.1 M glycine in PBS for 5 min, 1ϫ PBS for 5 min, and 0.1 M triethanolamine-0.25% acetic anhydride for 10 min. Slides were prehybridized in prehybridization-hybridization buffer (50% formamide, 4ϫ SSC, 1ϫ Denhardt's solution, 4 mM NaPO 4 , 0.1% SDS, 5% dextran sulfate, 250 g of tRNA per ml, 250 g of salmon sperm DNA per ml in DEPC water) in a preheated humidity chamber under a coverslip for 15 min. The probe was added to the hybridization buffer to a final concentration of 2.5 ng/ml, and the slides were placed under coverslips, sealed with rubber cement, heated to 65ЊC for 5 min, chilled on ice, and incubated overnight at 50ЊC. Following hybridization, the coverslips were removed and the sections were washed in 2ϫ SSC-50% formamide solution at 50ЊC for 5 min and then for 1 h, twice for 1 min in 2ϫ SSC, and for 30 min in an RNase solution at 37ЊC (RNase T 1 and RNase A in 2ϫ SSC). These washing steps were repeated, and the slides were blocked with a buffer containing 2% horse serum, 0.3% Tween 20, 150 mM NaCl, and 100 mM Tris (pH 7.4) for 1 h. Following the blocking, the slides were incubated for 1 h with sheep antidigoxigenin alkaline phosphatase conjugate at a 1:5,000 dilution in PBS-2% horse serum, were washed twice, and were incubated with nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate toluidinium (NBT-BCIP) substrate in the dark at room temperature for 2 h. The slides were counterstained with nuclear fast red, dehydrated, and placed under coverslips.
RESULTS

Kinetics of SIVagm infection of PT macaques.
Virus was isolated in CEMss cells from cryopreserved splenic homogenates collected at necropsy from PT63 and the splenic homogenate, and the isolate (SIVagm9063) was inoculated into a total of eight PT macaques (four per virus preparation). The splenic homogenate was used to avoid tissue culture selection that might result in viral attenuation. All eight animals became persistently infected, as evidenced by the isolation of virus from PBMC and/or seroconversion, and the outcome of infection in these animals is shown in Table 1 . The disease outcome did not appear to be affected by whether animals received the homogenate or the culture supernatant. Infection was characterized by an early plasma antigenemia in all of the animals and clinically by anorexia and lethargy during the acute phase of infection. Immunoreactivity of sequential plasma samples (Fig. 1 ) demonstrated seroconversion to SIVagm antigens in five animals by week 4 postinoculation, a transient response in two animals (PT287 and PT292), and failure to seroconvert in one animal (PT293). The levels of antigen in plasma were assessed by antigen capture as detailed in Table 2 . Generally, antigen was detected during only the acute phase of the infection (after 1 to 2 weeks); however, plasma antigenemia persisted throughout the period of infection in a few of the animals. The persistence of antigenemia correlated with the presence or absence of SIV-specific antibody. Thus, antigenemia was transient in the five animals that seroconverted, whereas antigenemia persisted (or fluctuated) in animals without SIV-specific antibody, such as PT293.
The kinetics of sequential antigenemia, lymphocyte subset alterations, and hematologic changes during the course of infection are detailed for four representative PT macaques in Fig. 2 . An acute viremia that coincided with marked hematologic changes was observed in all animals ( Table 2) . Contemporary controls that were sham inoculated were not included in this study; however, such alterations were not observed in previous studies of such controls (data not shown). Hematologic changes included severe leukopenia, lymphopenia, moderate anemia, and thrombocytopenia. The lymphopenia which affected all subsets was coincident with antigenemia (days 7 to 14). Striking hematologic alterations during the acute phase of infection were also observed; data indicating transient thrombocytopenia coincident with plasma viremia and a concurrent but slower decline in the numbers of erythrocytes (measured by changes in the hematocrit level) can be observed in Fig. 2 . The mechanism of this pancytopenia was not determined, but the effects may be due to a transient failure of hematopoiesis or release from the bone marrow compartment. Whereas the changes in platelet numbers and leukocytes are clearly related to the viral infection, the intensive bleeding schedule may have contributed to the alterations in hematocrit. In historical studies, however, the anemia observed in uninfected animals bled as intensively as these was significantly less profound. In addition to hematologic changes, all animals were anorexic and lethargic during the first 2 weeks of infection.
Whereas the kinetics of infection during the first 2 weeks of infection were similar for all animals, the subsequent clinical outcome varied significantly, with progression to AIDS ranging from 4 months to greater than 2.5 years from inoculation. All of the animals have evidenced either a rapid or slow decline in Fig. 2 . Fulminant infection was observed in one animal (PT293); PT293 never recovered preinoculation lymphocyte subset values, remained persistently viremic and antigenemic, experienced an abrupt decline in all lymphocyte subsets, and was sacrificed at 20 weeks postinoculation. In contrast, the infection in PT287 was characterized by transient plasma antigenemia and a partial recovery followed by clinical deterioration within 1 year of infection. As shown by Fig. 2 , circulating lymphocyte levels of PT287 rebounded transiently and then plummeted between 24 to 32 weeks postinfection, coincident with a rise in plasma antigen levels and a deteriorating clinical condition. Relatively slow progression to AIDS was observed for about half the animals. Two of these animals (PT232 and PT308; Fig. 2 ) cleared the initial plasma antigenemia and remained clinically stable for 2 years postinoculation. However, despite their longer survival, a progressive decline in CD4 lymphocyte levels and clinical progression of these animals have also been seen. For example, in PT232, a progressive loss of CD4 lymphocytes and persistent thrombocytopenia in 
a Plasma antigenemia was measured by the SIV p27 antigen capture kit (Coulter Corp.). -, SIV p27 was not detected in the plasma sample. SIV-specific antibody (SIV Ab) was detected by Western blot analysis; PT287 and PT292 exhibited transient antibody responses, PT293 exhibited no response, and all other animals exhibited sustained responses. D, dead; NT, not tested; AGM, African green monkey.
b Pre, sample taken preinoculation.
FIG. 2.
Alterations in lymphocyte subsets, hematologic parameters, virus isolation from PBMC, and SIV p27 plasma antigenemia during the course of infection of four PT macaques (PT293, PT287, PT232, and PT308) infected with uncloned SIVagm9063. Parameters for four animals representative of the spectrum of disease survival are shown. PT293 is representative of the fulminant disease observed in animals with an ineffective immune response. The arrows indicate the time of necropsy. The bar graphs in the top panel demonstrate the levels of antigen in plasma for various weeks postinfection. n.t., antigen was not tested; D, dead. The plus and minus signs above the columns indicate the results of attempts to isolate virus from 5 ϫ 10 6 PBMC. The absolute numbers of circulating lymphocyte subsets are graphed in the middle panels, and the hematologic alterations are charted in the bottom panels. A marked panleukopenia affecting all leukocyte subsets in all animals was observed coincident with a peak of plasma viremia. A concurrent decline in platelet counts and a slower decline in hematocrit levels in all animals were also observed. Following the acute viremia, these parameters returned to near the baseline for two animals, PT232 and PT308; however, the deteriorating clinical condition of PT287 coincided with a decline in CD4, CD8, and B lymphocytes prior to death. Three of the animals (PT293, PT232, and PT287) also exhibited persistent thrombocytopenia, and one animal (PT293) was severely anemic prior to death.
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on Antigen levels, lymphocyte subsets, and hematologic parameters for two rhesus and two African green monkeys experimentally infected with SIVagm uncloned virus. As in Fig. 2 , the top panels show plasma p27 antigen levels, the middle panels show lymphocyte subsets, and the bottom panels depict hematologic changes of two rhesus macaques and two African green monkeys infected with uncloned SIVagm9063. In contrast to the findings for PT macaques (Fig. 2) , only one rhesus macaque had detectable plasma viremia. However, similarly to the PT macaques, rhesus macaques exhibited panleukopenia during the first week of infection. Lymphocyte numbers returned rapidly to and remained within the normal range. In contrast to the PT macaques, the rhesus macaques exhibited no thrombocytopenia or anemia. No alterations were observed in the lymphocyte subsets or hematologic parameters of the infected African green monkeys. Virus isolation from PBMC (shown above the column for each week) was less consistent than that from PBMC of PT macaques;
both of the infected rhesus macaques appeared to experience a transient viremia. Pathologic lesions consistent with an immunodeficiency syndrome. Infection of PT macaques was associated with lymphadenopathy, splenomegaly, failure to thrive, and chronic diarrhea. Animals were sacrificed and a full necropsy was performed if they developed chronic persistent weight loss, diarrhea that did not respond to supportive therapy, or clinical evidence of an opportunistic infection or neoplasm. The outcome in terms of survival is summarized in Table 1 . A spectrum of AIDS-related pathology in the necropsied PT macaques was observed, although a consistent feature was lymphoid depletion. The causes of death varied: (i) aplastic anemia and meningoencephalitis for PT293, (ii) bacterial endocarditis for PT231 and PT308, (iii) protozoal encephalitis and tarsal bone abscess for PT287, (iv) M. avium enteritis and lymphadenitis for PT63, (v) pulmonary artery thrombosis for PT250, and (vi) generalized osteoarthropathy of unknown etiology for PT300. Other more-minor lesions included oral and esophageal candidiasis (PT293), a granulomatous pneumonia (PT293 and PT287), severe enteritis with crypt abscessation (PT293), and severe thrombocytopenia (PT293, PT231, PT287, and PT250). Meningoencephalitis with multinucleated giant cells was also observed for two animals (PT293 and PT287). General lesions included lymphoid depletion which varied from moderate to severe and involved both lymphoid follicles and paracortical regions. In some lymph nodes, there was evidence of syncytium formation, particularly within the sinusoids. Severe generalized lymphoid depletion was evident in tissues of PT293, the animal with rapid disease progression. A spectrum of pathologic lesions are depicted in Fig. 4 . Thus, as with SIVmac infection of macaques, these animals had evidence of opportunistic infections and brain lesions reminiscent of human AIDS dementia symptoms.
Whereas the lymphoid depletion and opportunistic infections observed were similar to those of human AIDS, there were some subtle differences. First, the disease course was more rapid. Second, some unusual pathologic lesions, such as aplastic anemia, and proliferative osteoarthropathy, were observed in some animals. The etiology of these lesions is not known, but since they are not commonly observed in uninfected macaques they are presumed to be associated (directly or indirectly) with SIV infection. Finally, a number of the animals developed overwhelming bacterial infections, a manifestation which has not generally been associated with human AIDS. Since these syndromes have never been observed in uninfected macaques obtained from a common source (data not shown), these infections are assumed to be due to immune dysfunction related to the SIV infection.
Lack of disease in rhesus macaques and African green monkeys. Previous studies utilizing the SIVagm90 parental virus had demonstrated immunodeficiency in PT macaques but not rhesus macaques. To assess the species specificity of disease, two naive African green monkeys (C. sabaeus) and two rhesus macaques were inoculated with the uncloned macaque-passaged isolate. All four animals became infected; however, virus isolation from sequential PBMC samples was inconsistent and thus suggestive of a low viral load. In contrast to results for the infected PT macaques, SIV p27 antigen was not detected in sequential plasma samples collected from one of the rhesus macaques or either African green monkey (Table 2 and Fig. 3) . A low level of SIV antigen was detected in plasma samples from RH229 at 1 week postinoculation but not at later time points. Lymphocyte subsets remained within normal limits for the infected African green monkeys. A gradual decline in CD4 lymphocytes (but not CD8 cells) was observed for both infected rhesus macaques; however, at present (1 year postinfection) the absolute numbers of CD4 lymphocytes have remained within normal limits for this species. The rhesus macaques also experienced a transient lymphopenia during the first week of infection, whereas no definitive change in lymphocyte subsets was observed for the African green monkeys. None of these infected rhesus macaques or African green monkeys have developed indications of clinical disease, including secondary symptoms such as lymphadenopathy, splenomegaly, anemia, or thrombocytopenia, signs frequently observed in the PT macaques.
Molecular cloning and characterization of SIVagm9063. Molecular clones were derived to determine the relationship of this isolate to other vervet isolates and the etiology of the immunodeficiency syndrome. Three full-length clones were generated from a bacteriophage lambda library of total cellular DNA extracted from the CEMss isolate from PT63 spleen. The sequence of the SIVagm9063-2 provirus (ϳ9,000 bp) was determined. The genome was similar in organization to that of other previously characterized SIVagm clones: it encoded the classical gag, pol, and env genes in addition to vif, tat, rev, nef, and vpr. As shown in Table 3 , the amino acid identities of these various protein products are similar to those of other SIVagm clones derived from vervet species of African green monkey. The binding motif for NF-B within the long terminal repeat (LTR) is duplicated as in other SIVagm clones (22) . Since the virus sequence was derived from an isolate following animal passage, the divergence from the parental Agm90 isolate was of particular interest. The envelope and LTR sequences of the parental strain (SIV agm90 ) were compared with those of the PT63-passaged strain (SIV agm9063 ). The LTR of the Agm90 isolate had been analyzed previously (22) and was 96% similar in terms of nucleotide sequence to the PT-passaged virus LTR. To assess the degree of evolution during macaque strain passage, the envelope of the parental Agm90 virus was cloned and the predicted amino acid sequence was compared to that of clone 2. Surprisingly, the envelope genes were highly conserved, suggesting minimal evolution during macaque strain passage.
Demonstration of SIV expression in tissues. An in situ hybridization technique for SIVagm mRNA was developed to determine the tissue and cellular distributions of the virus. This was necessary because SIVagm-specific antisera are not readily available and no viral antigen was detectable with SIVmneE11S-specific rabbit polyclonal serum (data not shown). A series of clones that spanned the entire genome of SIVagm9063-2 were generated by PCR amplification using the full-length clone as a template. These products were cloned by using BamHI and EcoRI sites introduced by the PCR primers used for amplification into a plasmid containing the Sp1 and T7 promoters (pGEM-7Zf; Promega). The plasmids were linearized with BamHI (for T7 transcription for antisense RNA) or EcoRI (for SP6 transcription for sense RNA).
In situ hybridization was performed on a variety of lymphoid and nonlymphoid tissues from two PT macaques. As shown in Fig. 5 , the antisense probe hybridized to numerous cells within lymphoid tissues, lung, and brain. In contrast, no signal was detected in the same tissues when the sense probe was utilized or when the antisense probe was used to examine lymph node sections from an uninfected PT macaque. Thus, the hybridization is specific both for SIV and for message-sense RNA. As expected on the basis of the tropism of this virus, the signal was localized to lymphocytes, macrophages, and multinucleated giant cells (syncytial cells). The distribution was similar to that observed for SIVsm-SIVmac immunohistochemistry or in situ hybridization (21, 37, 39) : scattered infected cells were observed within the paracortex of lymph nodes, the periartieriolar lymphoid sheaths of the spleen, and occasionally within multinucleated giant cells. In addition, viral RNA was detected in macrophages and multinucleated giant cells within granulomatous lesions in the lungs and in multinucleated cells within the brains and meninges of both animals (Fig. 5) . In contrast to the high level of viral expression in tissues of immunodeficient FIG. 6 . Alterations in absolute numbers of circulating CD4 lymphocytes and levels of SIV p27 antigenemia during the course of infection of PT macaques with cloned SIVagm9063-2. The data have been grouped into those for animals that developed AIDS (on the left), those for animals that remained healthy for approximately 21 months (in the middle), and historical data on sequential samples collected from a cohort of uninfected (mock-infected) PT macaques (on the right). While no obvious trend in CD4 counts was observed for the uninfected control group, the SIVagm9063-2-infected animals all experienced a sharp decline in the number of circulating CD4 lymphocytes (and other subsets; data not shown) coincident with development of plasma viremia. Those animals that developed AIDS included three which were autopsied (Table 3 ) and one surviving macaque (PT491) that is immunodeficient. The top panel depicts changes in CD4 lymphocyte numbers during the course of infection. The CD4 counts continued to decline in those animals that developed AIDS, whereas they slowly returned to within normal limits in those animals that did not develop AIDS. In the panels below, the bar graphs show the SIV p27 antigen levels in plasma at the same time points. The symbol for each animal is shown beside the bar graphs. The degree of plasma antigenemia during the acute phase of infection did not appear to correlate with the rapidity of the clinical course; the persistence of plasma viremia, however, was a clear correlate with a poor outcome. PT macaques (Fig. 5) , only occasional cells expressing viral mRNA (fewer than one per high-power field) were detected in lymph node biopsies obtained at 1 year postinoculation from either of the healthy SIVagm9063-infected rhesus macaques or the African green monkeys.
Biologic activities of SIVagm clones in vitro and in vivo. Biologic activities of the three full-length clones were assessed by transfection of 293 and CEMss cells. Both clones 2 and 7 produced RT following transient transfection of 293 cells (Table 4); however, only clone 2 was infectious following transfection of CEMss cells. In addition, cell-free supernatant from 293 cells transfected with clone 2 was infectious for PT macaque PBMC (within 7 to 10 days). A virus stock representing clone 2 generated in macaque PBMC, which efficiently infected PT macaque PBMC and monocyte-derived macrophages, was used for subsequent animal studies.
Infectivity and pathogenicity of SIVagm9063-2 molecularly cloned virus was assessed following inoculation of eight PT macaques. All the animals became persistently infected as evidenced by virus isolation from PBMC and were transiently anorexic and lethargic. The cloned virus reproduced the kinetics of infection observed with parental uncloned virus stock. Thus, as seen by the data in Fig. 6 , all the animals were acutely antigenemic and experienced a concurrent leukopenia (only CD4 is graphed). All the animals also experienced a transient anemia and thrombocytopenia (data not shown). During the 14 months after inoculation (Table 5) , many of the animals experienced significant persistent thrombocytopenia, CD4 depletion, weight loss, anorexia, failure to thrive, or chronic diarrhea; these clinical signs were life threatening and necessitated euthanasia of three macaques. Preliminary pathologic analyses demonstrated severe lymphoid depletion, meningoencephalitis (n ϭ 1), M. avium infection (n ϭ 1), P. carinii pneumonia (n ϭ 1), and lymphoreticular sarcoma (n ϭ 1). These data indicate that the molecularly cloned virus induces the same AIDS-like syndrome observed with the parental virus. One animal (PT485) developed the fulminant disease also observed in one macaque infected with uncloned SIVagm. However, the progression of disease appeared to be somewhat slower than that observed with the uncloned virus and two of the animals have maintained normal lymphocyte subsets that may be predictive of long-term survival. These studies demonstrate that SIVagm isolates are capable of inducing an AIDSlike syndrome that can be definitively associated with viral infection.
DISCUSSION
This report describes the isolation of a SIVagm strain with species-specific pathogenicity and the derivation of a representative pathogenic molecular clone. The SIVagm9063 isolate induced an immunodeficiency syndrome similar to that reported in SIVsm-and SIVmac-infected macaques (21, 30, 31, 34, (38) (39) (40) . This finding contrasts with the previous reports of experimental SIVagm infection in which no disease was observed (1, 22, 24) . A consistent acute viremia with a coincident decline in the levels of all lymphocyte subsets, followed by a progressive depletion of CD4 lymphocytes, was observed for all PT macaques inoculated with this SIVagm isolate. Half of the study animals were euthanized within 1 year of inoculation because of wasting, chronic diarrhea, clinical deterioration, and/or opportunistic infections. Pathologic features included generalized severe lymphoid depletion in association with opportunistic infections and, in some cases, SIV-induced meningoencephalitis. In situ hybridization for SIV mRNA expression in tissues demonstrated that this syndrome was associated with high levels of viral expression in lymphoid and some nonlymphoid tissues (i.e., brain and lung). Viral expression appeared to be generally restricted to lymphocytes, macrophages, and multinucleated giant cells, similarly to the distribution of SIVsm and SIVmac in infected animals (35, 38) . Finally, a molecular clone of this virus strain reproduced the immunodeficiency disease of the parental uncloned virus strain, thus providing an etiologic link between the virus and the disease. Despite the derivation of increasing numbers of full-length infectious SIV clones, few cloned viruses are pathogenic upon inoculation of susceptible hosts or reproduce the pathogenic potential of uncloned viruses. Thus, this is only the third report of a highly pathogenic SIV cloned virus and the first report of a pathogenic SIVagm cloned virus. Other pathogenic molecular clones have represented a SIVmac-SIVsm subtype. One of these viruses (SIVmac239) induces an AIDS-like syndrome (28) , whereas the other virus, SIVsmmPBj (12, 35) , induces a novel acutely lethal diarrheal syndrome (15) rather than classical immunodeficiency. The reproduction of disease with the SIVagm molecularly cloned virus confirms that this syndrome results from SIV infection and not from other adventitious agents that might have been passaged with the parental uncloned virus stock.
Despite the profound immunosuppression observed in PT macaques, inoculation of rhesus macaques, a related species, did not result in obvious disease. In addition, although exper- (15, 32, 35) . The unique disease susceptibility of SIVagm9063 may partially explain previous reports of attenuation of SIVagm, since most previous studies utilized African green monkeys, rhesus macaques, or cynomolgus macaques. At least two of these species are not susceptible to SIVagm9063-induced immunodeficiency. Thus, other SIVagm isolates (particularly those from vervet monkeys) might be equally pathogenic if tested in an appropriate animal model. This variation in susceptibility also underscores the pitfalls of designating a SIV strain attenuated, since the host response determines at least in part the pathogenicity of the virus. Finally, the SIVagm animal model provides a basis to study host variation in response to infection. This model has an advantage over the SIVsm-SIVmac macaque models in that both the highly susceptible and natural host species are readily available for study, whereas few sooty mangabey monkeys, the natural host of SIVsm-SIVmac viruses, are available for experimental studies. The underlying mechanism(s) for the differential host response to this virus is a still a matter for speculation. Whereas PT macaques were highly viremic during the acute phase of infection, viral replication appeared to be highly restricted in both rhesus macaques and African green monkeys. Low-to-absent plasma viremia levels during the acute phase of infection in rhesus and African green monkeys suggest that virus replication is less efficient than that in infected PT macaques. Thus, low-level plasma viremia was detected in only one rhesus macaque, virus isolation was inconsistent, SIVspecific antibody levels rose more slowly than in PT macaques despite the absence of plasma viremia, and only rare SIVexpressing cells were observed by in situ hybridization of lymph nodes. These data are consistent with inefficient in vivo replication and maintenance of a light viral load in rhesus macaques and African green monkeys. Thus, the differential virulence of this virus is likely associated with the extent and efficiency of in vivo replication in these three species of primate. Interestingly, in vitro replication in rhesus macaque PBMC and macrophages was a poor predictor of in vivo pathogenicity in rhesus macaques. Further studies will be required to delineate differences in the host immune response or viral replication that determine the species-specific pathogenesis of this virus.
